#France #Servier #Suresnes #Sevasemten #Edgewise

Servier's Strategic Acquisition of Edgewise Therapeutics

On June 1, 2026, Servier, a prominent independent pharmaceutical group, revealed that it has entered into a strategic agreement to acquire the muscular dystrophy operations of Edgewise Therapeutics Inc. This decision represents a significant step towards Servier's ambition to enhance its portfolio in the realm of rare neurological diseases, particularly as patients with muscular dystrophies face significant unmet medical needs.

The acquisition deal is valued at up to $2.65 billion, which includes an initial payment of $1.55 billion, with additional regulatory and commercial milestone payments of up to $1.1 billion. This transaction has already seen approvals from the respective governance boards of both companies, while still pending regulatory approvals and customary closing conditions, projected for completion in the third quarter of 2026.

About the Acquisition

Included in the acquisition are the talented teams from Edgewise's muscular dystrophy unit and their advanced-stage experimental treatment known as sevasemten. This innovative oral myosin inhibitor is designed to preserve and protect muscles from damage caused by contraction in patients suffering from rare muscular dystrophies. Currently, sevasemten is undergoing pivotal assessment for Becker muscular dystrophy (BMD) and is in phase 2 trials for Duchenne muscular dystrophy (DMD). It is anticipated that this candidate drug will firmly position Servier on the global stage, equipped with both operational capabilities and a robust pipeline focusing on neuromuscular disorders.

The Importance of Muscular Dystrophy Treatments

Becker muscular dystrophy is a rare genetic condition linked to the X chromosome, causing progressive muscle loss without any currently approved treatments available. The irreversible decline in muscle function severely impacts patients’ daily life activities, such as walking. In contrast, Duchenne muscular dystrophy is a more severe and recessive genetic disorder, also X-linked, that begins from birth, often leading to a complete loss of walking ability in teenage years. DMD is the most prevalent form of muscular dystrophy, with a median lifespan of approximately 30 years.

Olivier Laureau, President of Servier, stated, "Acquiring Edgewise Therapeutics’ muscular dystrophy business is a crucial step in realizing our Servier 2030 vision in neurology, supported by a team of talented experts and a promising asset in the muscular dystrophy realm. Our goal is to provide targeted therapies to patients afflicted with rare neuromuscular disorders who currently have limited or no treatment options. Developing treatments for both young and adult patients facing these debilitating rare diseases is at the heart of our mission.”

Conclusion

This acquisition not only enhances Servier's commitment to addressing the needs of patients with rare diseases but also signifies a broader effort to innovate in the pharmaceutical industry, particularly in the realm of neuromuscular disorders. By integrating Edgewise’s promising treatment and knowledgeable workforce, Servier aims to lead with advanced therapeutic solutions that could transform the lives of many patients around the world.